Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer

Belal Chaudhary, May Abd Al Samid, Basel K. Al-Ramadi, Eyad Elkord

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Introduction: Regulatory T cells (Tregs) have been characterised in different cancers. They accumulate in peripheral blood and tumour microenvironments where they suppress tumour-specific immune responses, enabling tumours to develop without challenge. This tumour immune evasion represents a major obstacle to successful cancer therapies. Whilst Tregs are generally divided into thymic-derived and peripherally induced, Tregs exhibit a wide spectrum of phenotypes and functional capacity dependent on microenvironment. This phenotypic diversity is also reflected in tumour-infiltrating Treg (TI Treg) populations, which may explain the variable impact of Treg accumulation on prognosis in different cancers. Identifying TI Treg subsets is critical to understand TI Treg biology and for developing effective immunotherapies. Areas covered: This review discusses current and potential markers, and the modulation of these markers in cancer. In addition, we systematically review the clinical impact of Tregs in cancer and their potential as a therapeutic target, with a focus on TI Tregs. Expert opinion: TI Tregs represent dynamic and diverse subsets that are key in promoting tumour progression through their suppressive activities. Targeting specific TI Treg subpopulations and functional TI Treg markers represents a feasible therapeutic strategy that might allow reestablishment of antitumour immune responses without affecting physiological immune regulation.

Original languageEnglish
Pages (from-to)931-945
Number of pages15
JournalExpert Opinion on Biological Therapy
Volume14
Issue number7
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

T-cells
Regulatory T-Lymphocytes
Tumors
Neoplasms
Therapeutics
Tumor Escape
Tumor Microenvironment
Expert Testimony
Blood
Modulation
Immunotherapy

Keywords

  • Cancer
  • Clinical impact
  • Regulatory T cells subsets
  • Therapeutic target
  • Treg markers

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery
  • Medicine(all)

Cite this

Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. / Chaudhary, Belal; Abd Al Samid, May; Al-Ramadi, Basel K.; Elkord, Eyad.

In: Expert Opinion on Biological Therapy, Vol. 14, No. 7, 2014, p. 931-945.

Research output: Contribution to journalReview article

Chaudhary, Belal ; Abd Al Samid, May ; Al-Ramadi, Basel K. ; Elkord, Eyad. / Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. In: Expert Opinion on Biological Therapy. 2014 ; Vol. 14, No. 7. pp. 931-945.
@article{4ad8a12f21f34120879f0fed3afd6980,
title = "Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer",
abstract = "Introduction: Regulatory T cells (Tregs) have been characterised in different cancers. They accumulate in peripheral blood and tumour microenvironments where they suppress tumour-specific immune responses, enabling tumours to develop without challenge. This tumour immune evasion represents a major obstacle to successful cancer therapies. Whilst Tregs are generally divided into thymic-derived and peripherally induced, Tregs exhibit a wide spectrum of phenotypes and functional capacity dependent on microenvironment. This phenotypic diversity is also reflected in tumour-infiltrating Treg (TI Treg) populations, which may explain the variable impact of Treg accumulation on prognosis in different cancers. Identifying TI Treg subsets is critical to understand TI Treg biology and for developing effective immunotherapies. Areas covered: This review discusses current and potential markers, and the modulation of these markers in cancer. In addition, we systematically review the clinical impact of Tregs in cancer and their potential as a therapeutic target, with a focus on TI Tregs. Expert opinion: TI Tregs represent dynamic and diverse subsets that are key in promoting tumour progression through their suppressive activities. Targeting specific TI Treg subpopulations and functional TI Treg markers represents a feasible therapeutic strategy that might allow reestablishment of antitumour immune responses without affecting physiological immune regulation.",
keywords = "Cancer, Clinical impact, Regulatory T cells subsets, Therapeutic target, Treg markers",
author = "Belal Chaudhary and {Abd Al Samid}, May and Al-Ramadi, {Basel K.} and Eyad Elkord",
year = "2014",
doi = "10.1517/14712598.2014.900539",
language = "English",
volume = "14",
pages = "931--945",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer

AU - Chaudhary, Belal

AU - Abd Al Samid, May

AU - Al-Ramadi, Basel K.

AU - Elkord, Eyad

PY - 2014

Y1 - 2014

N2 - Introduction: Regulatory T cells (Tregs) have been characterised in different cancers. They accumulate in peripheral blood and tumour microenvironments where they suppress tumour-specific immune responses, enabling tumours to develop without challenge. This tumour immune evasion represents a major obstacle to successful cancer therapies. Whilst Tregs are generally divided into thymic-derived and peripherally induced, Tregs exhibit a wide spectrum of phenotypes and functional capacity dependent on microenvironment. This phenotypic diversity is also reflected in tumour-infiltrating Treg (TI Treg) populations, which may explain the variable impact of Treg accumulation on prognosis in different cancers. Identifying TI Treg subsets is critical to understand TI Treg biology and for developing effective immunotherapies. Areas covered: This review discusses current and potential markers, and the modulation of these markers in cancer. In addition, we systematically review the clinical impact of Tregs in cancer and their potential as a therapeutic target, with a focus on TI Tregs. Expert opinion: TI Tregs represent dynamic and diverse subsets that are key in promoting tumour progression through their suppressive activities. Targeting specific TI Treg subpopulations and functional TI Treg markers represents a feasible therapeutic strategy that might allow reestablishment of antitumour immune responses without affecting physiological immune regulation.

AB - Introduction: Regulatory T cells (Tregs) have been characterised in different cancers. They accumulate in peripheral blood and tumour microenvironments where they suppress tumour-specific immune responses, enabling tumours to develop without challenge. This tumour immune evasion represents a major obstacle to successful cancer therapies. Whilst Tregs are generally divided into thymic-derived and peripherally induced, Tregs exhibit a wide spectrum of phenotypes and functional capacity dependent on microenvironment. This phenotypic diversity is also reflected in tumour-infiltrating Treg (TI Treg) populations, which may explain the variable impact of Treg accumulation on prognosis in different cancers. Identifying TI Treg subsets is critical to understand TI Treg biology and for developing effective immunotherapies. Areas covered: This review discusses current and potential markers, and the modulation of these markers in cancer. In addition, we systematically review the clinical impact of Tregs in cancer and their potential as a therapeutic target, with a focus on TI Tregs. Expert opinion: TI Tregs represent dynamic and diverse subsets that are key in promoting tumour progression through their suppressive activities. Targeting specific TI Treg subpopulations and functional TI Treg markers represents a feasible therapeutic strategy that might allow reestablishment of antitumour immune responses without affecting physiological immune regulation.

KW - Cancer

KW - Clinical impact

KW - Regulatory T cells subsets

KW - Therapeutic target

KW - Treg markers

UR - http://www.scopus.com/inward/record.url?scp=84902176332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902176332&partnerID=8YFLogxK

U2 - 10.1517/14712598.2014.900539

DO - 10.1517/14712598.2014.900539

M3 - Review article

C2 - 24661020

AN - SCOPUS:84902176332

VL - 14

SP - 931

EP - 945

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 7

ER -